Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTLBiotechnology
+$0.03 today
- Market cap
- $133.64M
- Beta
- 1.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.77
Volume 1.21M
Average 2.00M
ZNTL Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Zentalis Pharmaceuticals, Inc.NASDAQ: ZNTL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $151K fell 42.4% year over year, ahead of the -48.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.8% from the prior quarter. Over 3 fiscal years it compounded at -19.7% a year.
Context
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -42.4% holds above the trailing-twelve-month pace of -48.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 739K USD
- Year-over-year change
- -42.7%
- 4-year CAGR
- +8.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 739K | -42.7% |
| FY2024 | 2024-12-31 | 1.29M | -7.2% |
| FY2023 | 2023-12-31 | 1.39M | -2.6% |
| FY2022 | 2022-12-31 | 1.43M | +162.1% |
| FY2021 | 2021-12-31 | 544K | — |
Depreciation & Amortization vs competitors
How ZNTL compares with its peers on the latest reported figures
- ZNTL's LTM Mar 2026 depreciation & amortization of $628K is the 8th largest of the 11 companies compared; the peer median is $2.1M.
- Its year-over-year change of -48.8% is the 9th highest of 11, against a peer median of -17.3%.
- Over three fiscal years its annual growth of -19.7% compares with a peer median of +1.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.94M | -7.1% | -22.5% | 4.4% | |
| LTM Mar 2026 | $6.7M | -8.9% | +8.8% | 6.7% | |
| LTM Mar 2026 | $3.64M | -3.9% | +6.3% | 364.3% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $2.71M | +9.6% | +30.9% | — |
| LTM Mar 2026 | $2.69M | -30.3% | -32.6% | 6.0% | |
| LTM Mar 2026 | $1.51M | -26.6% | -2.4% | — | |
| LTM Mar 2026 | $645K | -25.8% | +27.3% | — | |
| LTM Mar 2026 | $628K | -48.8% | -19.7% | — | |
| LTM Mar 2026 | $436.09K | +189.3% | +454.8% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $79K | -59.1% | -20.8% | 1.1% |
| LTM Mar 2026 | $48K | -98.5% | -55.3% | — | |
| Peer median (excluding ZNTL) | $2.1M | -17.3% | +1.9% | 6.0% | |
Competitors are the stored peer set for ZNTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (166.09M) | (237.11M) | (292.19M) | (165.87M) | (137.06M) |
| Depreciation & Amortization | 544K | 1.43M | 1.39M | 1.29M | 739K |
| Deferred Income Tax | (2.51M) | (769K) | (853K) | 0 | 0 |
| Stock-Based Compensation | 35.74M | 46.84M | 54.82M | 67.27M | 20.72M |
| Change in Working Capital | 16.61M | 13.25M | 5.86M | (16.54M) | (9.12M) |
| Accounts Receivables | 413K | 0 | 0 | (5M) | 5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 13.96M | 15.53M | 10.92M | (18.02M) | (17.32M) |
| Other Working Capital | 2.23M | (2.28M) | (5.06M) | 6.48M | 3.19M |
| Other Non-Cash Items | (38.38M) | 12.61M | 23.15M | (57.01M) | (526K) |
| Operating Cash Flow | (154.09M) | (163.75M) | (207.82M) | (170.86M) | (125.25M) |
| Capital Expenditures | (6.11M) | (2.55M) | (583K) | (221K) | 0 |
| Acquisitions (Net) | (14.32M) | 111.63K | 0 | 65K | 0 |
| Purchases of Investments | (363.51M) | (533.16M) | (549.18M) | (127.96M) | (139.49M) |
| Sales of Investments | 365.82M | 421.53M | 505.31M | 304.68M | 270.41M |
| Other Investing Activities | 0 | (111.63K) | 0 | 0 | 698K |
| Investing Cash Flow | (18.12M) | (114.18M) | (44.46M) | 176.56M | 131.62M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 179.67M | 261.04M | 237.3M | 349K | (4.28M) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.15M) | 0 | 0 | (241K) | 0 |
| Financing Cash Flow | 178.52M | 261.04M | 237.3M | 108K | (4.28M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 6.31M | (16.89M) | (14.98M) | 5.81M | 2.09M |
| Free Cash Flow | (160.2M) | (166.3M) | (208.41M) | (171.08M) | (125.25M) |
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
Intrinsic Alpha fair value
Locked
Current Price
$1.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.